Marie Bruun
Marie Bruun has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Kristian Steen Frederiksen
Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5 shared publications Gunhild Waldemar
Danish Dementia Research Centre
3 shared publications- Le Gjerum
Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
3 shared publications - Mark van Gils
Tampere University
3 shared publications - Marta Baroni
Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy
3 shared publications Afina W. Lemstra
Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 28 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 655-664
Older adults’ attitudes toward knowing their risk of Alzheimer's disease and preclinical diagnostic communication: A nationwide study
Background: Communication about biomarkers and disclosure of Alzheimer's disease pathology is challenging. Earlier diagnosis has intensified this challenge, but evidence regarding communication of positive biomarker results for Alzheimer's disease to individuals with subjective cognitive decline remains limited. Objective: The study aimed to investigate older adults’ attitude toward knowing their risk of Alzheimer's disease, preferences regarding pre-biomarker counseling and diagnostic disclosure, and their views on the use of artificial intelligence in the diagnostic process when presented with a hypothetical scenario of subjective cognitive decline. Methods: We conducted a cross-sectional nationwide questionnaire survey among an age-selected, sex- and residence-balanced sample from the Danish Civil Registration System where individuals with dementia, nursing home residency, or dementia medication use were excluded. An online questionnaire was sent to 30,000 participants. Results: A total of 12,939 participants (aged 55–84 years, 53.3% female) answered at least one questionnaire item (response rate: 43.1%). More than two-thirds of the participants were interested in knowing their Alzheimer's disease risk status (76.4%). Information on treatment options, test reliability and risk prediction, along with written material, personal interaction and follow-up consultation, were rated as the most important topics. Simple graphical figures were preferred to accompany risk communication. Finally, 56.4% were positive toward use of artificial intelligence in diagnostics by physicians. Conclusions: Older adults are interested in knowing their risk of developing Alzheimer's disease and trust physicians’ use of artificial intelligence in the diagnostic process. Moreover, their preferences regarding information and methodology may help improve the current guidelines.
- 28 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 655-664
Older adults’ attitudes toward knowing their risk of Alzheimer's disease and preclinical diagnostic communication: A nationwide study
Background: Communication about biomarkers and disclosure of Alzheimer's disease pathology is challenging. Earlier diagnosis has intensified this challenge, but evidence regarding communication of positive biomarker results for Alzheimer's disease to individuals with subjective cognitive decline remains limited. Objective: The study aimed to investigate older adults’ attitude toward knowing their risk of Alzheimer's disease, preferences regarding pre-biomarker counseling and diagnostic disclosure, and their views on the use of artificial intelligence in the diagnostic process when presented with a hypothetical scenario of subjective cognitive decline. Methods: We conducted a cross-sectional nationwide questionnaire survey among an age-selected, sex- and residence-balanced sample from the Danish Civil Registration System where individuals with dementia, nursing home residency, or dementia medication use were excluded. An online questionnaire was sent to 30,000 participants. Results: A total of 12,939 participants (aged 55–84 years, 53.3% female) answered at least one questionnaire item (response rate: 43.1%). More than two-thirds of the participants were interested in knowing their Alzheimer's disease risk status (76.4%). Information on treatment options, test reliability and risk prediction, along with written material, personal interaction and follow-up consultation, were rated as the most important topics. Simple graphical figures were preferred to accompany risk communication. Finally, 56.4% were positive toward use of artificial intelligence in diagnostics by physicians. Conclusions: Older adults are interested in knowing their risk of developing Alzheimer's disease and trust physicians’ use of artificial intelligence in the diagnostic process. Moreover, their preferences regarding information and methodology may help improve the current guidelines.
- Open Access
- 12 January 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (5) , 3408-3421
Simultaneous multiple post-labelling delay ASL MRI and [18F]FDG PET in a mixed memory clinic population and healthy controls
Purpose: To assess the quantitative and visual concordance of multiple post-labelling delay (multi-PLD) arterial spin labelling (ASL) MRI cerebral blood flow (CBF) measurements and [ 18 F]-fluoro-deoxyglucose (FDG) PET in a mixed memory clinic population. Methods: Hybrid [ 18 F]FDG PET/MRI including multi-PLD pseudo continuous ASL from 96 memory clinic patients and 38 elderly controls were analysed along with ASL data from 12 healthy young volunteers. ASL image interpretability, concordance with [ 18 F]FDG PET, and value of Z-score maps were rated visually. Regional associations of CBF with [ 18 F]FDG uptake ratio (SUVr) were investigated by univariate regression and mixed linear models. Also influences of age, disease stage and vascular pathology on ASL interpretability and concordance, and whole cortex spatial coefficient of variation (sCOV) were analysed. Results: ASL CBF maps were non-comparable to [ 18 F]FDG PET, i.e. uninterpretable or discordant, in 53% of patients, 37% of elderly controls, and 8% of young controls. Only 14% of patient ASL MRI scans were concordant with [ 18 F]FDG PET. Z-score maps were mainly of value in partially concordant scans. Increasing sCOV was strongly associated both with disease severity and with decreasing ASL interpretability and concordance, and allowed for identification of uninterpretable scans with 95% sensitivity and 90% specificity. Whole cortex CBF and [ 18 F]FDG SUVr values showed similar distribution across groups, but low to moderate regional associations. Conclusions: Multi-PLD ASL provided quantitative CBF measurements correlating with disease severity, but poor image quality and low regional concordance in head-to-head comparison with [ 18 F]FDG PET imaging restricts the clinical use in memory clinic patients.
- 12 January 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (5) , 3408-3421
Open AccessSimultaneous multiple post-labelling delay ASL MRI and [18F]FDG PET in a mixed memory clinic population and healthy controls
Purpose: To assess the quantitative and visual concordance of multiple post-labelling delay (multi-PLD) arterial spin labelling (ASL) MRI cerebral blood flow (CBF) measurements and [ 18 F]-fluoro-deoxyglucose (FDG) PET in a mixed memory clinic population. Methods: Hybrid [ 18 F]FDG PET/MRI including multi-PLD pseudo continuous ASL from 96 memory clinic patients and 38 elderly controls were analysed along with ASL data from 12 healthy young volunteers. ASL image interpretability, concordance with [ 18 F]FDG PET, and value of Z-score maps were rated visually. Regional associations of CBF with [ 18 F]FDG uptake ratio (SUVr) were investigated by univariate regression and mixed linear models. Also influences of age, disease stage and vascular pathology on ASL interpretability and concordance, and whole cortex spatial coefficient of variation (sCOV) were analysed. Results: ASL CBF maps were non-comparable to [ 18 F]FDG PET, i.e. uninterpretable or discordant, in 53% of patients, 37% of elderly controls, and 8% of young controls. Only 14% of patient ASL MRI scans were concordant with [ 18 F]FDG PET. Z-score maps were mainly of value in partially concordant scans. Increasing sCOV was strongly associated both with disease severity and with decreasing ASL interpretability and concordance, and allowed for identification of uninterpretable scans with 95% sensitivity and 90% specificity. Whole cortex CBF and [ 18 F]FDG SUVr values showed similar distribution across groups, but low to moderate regional associations. Conclusions: Multi-PLD ASL provided quantitative CBF measurements correlating with disease severity, but poor image quality and low regional concordance in head-to-head comparison with [ 18 F]FDG PET imaging restricts the clinical use in memory clinic patients.
- Open Access
- 20 March 2019
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 11 (1) , 1-11
Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study
In clinical practice, it is often difficult to predict which patients with cognitive complaints or impairment will progress or remain stable. We assessed the impact of using a clinical decision support system, the PredictND tool, to predict progression in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) in memory clinics. In this prospective multicenter study, we included 429 patients with SCD (n = 230) and MCI (n = 199) (female 54%, age 67 ± 9, MMSE 28 ± 2) and followed them for at least 12 months. Based on all available patient baseline data (demographics, cognitive tests, cerebrospinal fluid biomarkers, and MRI), the PredictND tool provides a comprehensive overview of the data and a classification defining the likelihood of progression. At baseline, a clinician defined an expected follow-up diagnosis and estimated the level of confidence in their prediction using a visual analogue scale (VAS, 0–100%), first without and subsequently with the PredictND tool. As outcome measure, we defined clinical progression as progression from SCD to MCI or dementia, and from MCI to dementia. Correspondence between the expected and the actual clinical progression at follow-up defined the prognostic accuracy. After a mean follow-up time of 1.7 ± 0.4 years, 21 (9%) SCD and 63 (32%) MCI had progressed. When using the PredictND tool, the overall prognostic accuracy was unaffected (0.4%, 95%CI − 3.0%; + 3.9%; p = 0.79). However, restricting the analysis to patients with more certain classifications (n = 203), we found an increase of 3% in the accuracy (95%CI − 0.6%; + 6.5%; p = 0.11). Furthermore, for this subgroup, the tool alone showed a statistically significant increase in the prognostic accuracy compared to the evaluation without tool (6.4%, 95%CI 2.1%; 10.7%; p = 0.004). Specifically, the negative predictive value was high. Moreover, confidence in the prediction increased significantly (∆VAS = 4%, p < .0001). Adding the PredictND tool to the clinical evaluation increased clinicians’ confidence. Furthermore, the results indicate that the tool has the potential to improve prediction of progression for patients with more certain classifications.
- 20 March 2019
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 11 (1) , 1-11
Open AccessImpact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study
In clinical practice, it is often difficult to predict which patients with cognitive complaints or impairment will progress or remain stable. We assessed the impact of using a clinical decision support system, the PredictND tool, to predict progression in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) in memory clinics. In this prospective multicenter study, we included 429 patients with SCD (n = 230) and MCI (n = 199) (female 54%, age 67 ± 9, MMSE 28 ± 2) and followed them for at least 12 months. Based on all available patient baseline data (demographics, cognitive tests, cerebrospinal fluid biomarkers, and MRI), the PredictND tool provides a comprehensive overview of the data and a classification defining the likelihood of progression. At baseline, a clinician defined an expected follow-up diagnosis and estimated the level of confidence in their prediction using a visual analogue scale (VAS, 0–100%), first without and subsequently with the PredictND tool. As outcome measure, we defined clinical progression as progression from SCD to MCI or dementia, and from MCI to dementia. Correspondence between the expected and the actual clinical progression at follow-up defined the prognostic accuracy. After a mean follow-up time of 1.7 ± 0.4 years, 21 (9%) SCD and 63 (32%) MCI had progressed. When using the PredictND tool, the overall prognostic accuracy was unaffected (0.4%, 95%CI − 3.0%; + 3.9%; p = 0.79). However, restricting the analysis to patients with more certain classifications (n = 203), we found an increase of 3% in the accuracy (95%CI − 0.6%; + 6.5%; p = 0.11). Furthermore, for this subgroup, the tool alone showed a statistically significant increase in the prognostic accuracy compared to the evaluation without tool (6.4%, 95%CI 2.1%; 10.7%; p = 0.004). Specifically, the negative predictive value was high. Moreover, confidence in the prediction increased significantly (∆VAS = 4%, p < .0001). Adding the PredictND tool to the clinical evaluation increased clinicians’ confidence. Furthermore, the results indicate that the tool has the potential to improve prediction of progression for patients with more certain classifications.
- Open Access
- 1 January 2019
- Published by Elsevier in NeuroImage: Clinical
- Vol. 22, 101711
Detecting frontotemporal dementia syndromes using MRI biomarkers
- 1 January 2019
- Published by Elsevier in NeuroImage: Clinical
- Vol. 22, 101711
Open AccessDetecting frontotemporal dementia syndromes using MRI biomarkers
- Open Access
- 1 January 2018
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 10 (1) , 509-518
Evaluating combinations of diagnostic tests to discriminate different dementia types
Introduction: We studied, using a data‐driven approach, how different combinations of diagnostic tests contribute to the differential diagnosis of dementia.Methods: In this multicenter study, we included 356 patients with Alzheimer's disease, 87 frontotemporal dementia, 61 dementia with Lewy bodies, 38 vascular dementia, and 302 controls. We used a classifier to assess accuracy for individual performance and combinations of cognitive tests, cerebrospinal fluid biomarkers, and automated magnetic resonance imaging features for pairwise differentiation between dementia types.Results: Cognitive tests had good performance in separating any type of dementia from controls. Cerebrospinal fluid optimally contributed to identifying Alzheimer's disease, whereas magnetic resonance imaging features aided in separating vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. Combining diagnostic tests increased the accuracy, with balanced accuracies ranging from 78% to 97%.Discussion: Different diagnostic tests have their distinct roles in differential diagnostics of dementias. Our results indicate that combining different diagnostic tests may increase the accuracy further.
- 1 January 2018
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 10 (1) , 509-518
Open AccessEvaluating combinations of diagnostic tests to discriminate different dementia types
Introduction: We studied, using a data‐driven approach, how different combinations of diagnostic tests contribute to the differential diagnosis of dementia.Methods: In this multicenter study, we included 356 patients with Alzheimer's disease, 87 frontotemporal dementia, 61 dementia with Lewy bodies, 38 vascular dementia, and 302 controls. We used a classifier to assess accuracy for individual performance and combinations of cognitive tests, cerebrospinal fluid biomarkers, and automated magnetic resonance imaging features for pairwise differentiation between dementia types.Results: Cognitive tests had good performance in separating any type of dementia from controls. Cerebrospinal fluid optimally contributed to identifying Alzheimer's disease, whereas magnetic resonance imaging features aided in separating vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. Combining diagnostic tests increased the accuracy, with balanced accuracies ranging from 78% to 97%.Discussion: Different diagnostic tests have their distinct roles in differential diagnostics of dementias. Our results indicate that combining different diagnostic tests may increase the accuracy further.